Transaction in Own Shares

Summary by AI BETAClose X

Fevertree Drinks plc has announced the purchase of 127,130 ordinary shares between April 7th and April 10th, 2026, as part of its share buyback program. The volume-weighted average purchase price ranged from 769.06 pence to 817.03 pence per share, with individual transactions occurring on XLON and AIMX. The company intends to cancel these repurchased shares, which were acquired under the authority granted by shareholders at the 2025 Annual General Meeting.

Disclaimer*

Fevertree Drinks PLC
14 April 2026
 

14th April 2026                       

Fevertree Drinks plc

("Fever-Tree" or the "Company")

Transaction in Own Shares

 

Fevertree Drinks plc ("Fever-Tree" or the "Company") announces today it has, in accordance with the authority granted by shareholders at its 2025 Annual General Meeting held on 5th June, purchased the following number of ordinary shares of £0.0025 each in the Company (the "Ordinary Shares") through the Company's broker, Investec Bank plc ("Investec") in the period from 7th April to 10th April 2026.

Date

Venue

Volume-weighted average price (p)

Aggregated volume

Lowest price per share (p)

Highest price per share (p)

07 April 2026

XLON

769.0583

           25,209

748.0000

779.0000

07 April 2026

AIMX

776.0000

           20,000

776.0000

776.0000

08 April 2026

XLON

801.5459

             1,701

779.5000

804.0000

09 April 2026

XLON

805.0083

           40,209

802.0000

814.5000

10 April 2026

XLON

817.0306

           41,011

806.0000

824.0000

 

The Company intends to cancel the purchased shares.

   

Schedule of Purchases - Individual Transactions

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law by virtue of the European Union (Withdrawal) Act 2018, as amended), a full breakdown of the individual trades made by Investec on behalf of the Company as part of the share buyback programme is attached to this announcement.

 

http://www.rns-pdf.londonstockexchange.com/rns/2465A_1-2026-4-13.pdf

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

For further information please contact:

 

Investor queries

Steve Nightingale, Director of Investor Relations I steve.nightingale@fever-tree.com I +44 (0)7951 849564

 

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings